|Day Low/High||3.82 / 3.98|
|52 Wk Low/High||2.76 / 12.33|
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August 14, at 5:00pm EDT SAN DIEGO, Aug.
Company to host conference call and webcast at 5pm EDT / 2pm PDT
Dr. Briscoe to advise company on ongoing development of therapeutics based on the Neuropilin-2 (NRP2) co-receptor and related signaling pathways
TORONTO, July 24, 2019 /CNW/ - Evolve Funds Group Inc. ("Evolve") is pleased to announce the distribution amounts per unit (the "Distributions") for certain exchange traded funds (the "Evolve ETFs") for the period ending July 31, 2019, as indicated in the...
Conference Call Scheduled for Thursday, July 18th @ 2pm Eastern/11am Pacific
- Conference Call Today at 2:00 p.m. PT / 5:00 p.m. ET -
aTyr's ORCA program on-track to enter the clinic in 2019
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.